Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $188.53 Million

Equities analysts expect Omnicell, Inc. (NASDAQ:OMCL) to announce sales of $188.53 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Omnicell’s earnings. The highest sales estimate is $189.48 million and the lowest is $187.52 million. Omnicell reported sales of $180.89 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 4.2%. The company is scheduled to issue its next earnings results on Thursday, July 26th.

According to Zacks, analysts expect that Omnicell will report full year sales of $787.49 million for the current fiscal year, with estimates ranging from $785.06 million to $789.37 million. For the next fiscal year, analysts anticipate that the company will report sales of $868.17 million per share, with estimates ranging from $862.09 million to $873.11 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Omnicell.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, April 26th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.04. The firm had revenue of $182.60 million for the quarter, compared to analyst estimates of $177.49 million. Omnicell had a net margin of 4.55% and a return on equity of 4.11%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.06 EPS.

Several research firms have recently commented on OMCL. BidaskClub raised shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Saturday, May 5th. Benchmark began coverage on shares of Omnicell in a research report on Friday. They set a “buy” rating and a $63.00 price target on the stock. ValuEngine raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Wednesday, June 20th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $63.00 price target on shares of Omnicell in a research report on Tuesday, April 3rd. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $56.00.

In other Omnicell news, EVP Nhat H. Ngo sold 4,114 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The stock was sold at an average price of $52.00, for a total value of $213,928.00. Following the sale, the executive vice president now owns 61,864 shares of the company’s stock, valued at $3,216,928. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Peter J. Kuipers sold 724 shares of the business’s stock in a transaction that occurred on Thursday, April 12th. The shares were sold at an average price of $46.00, for a total value of $33,304.00. Following the completion of the sale, the insider now directly owns 56,970 shares in the company, valued at approximately $2,620,620. The disclosure for this sale can be found here. In the last three months, insiders sold 59,755 shares of company stock worth $2,840,350. 3.71% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Teachers Advisors LLC raised its position in Omnicell by 1.3% in the fourth quarter. Teachers Advisors LLC now owns 94,008 shares of the company’s stock valued at $4,559,000 after purchasing an additional 1,220 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in shares of Omnicell by 3.1% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 41,456 shares of the company’s stock worth $2,010,000 after acquiring an additional 1,233 shares during the period. California Public Employees Retirement System increased its position in shares of Omnicell by 1.6% during the fourth quarter. California Public Employees Retirement System now owns 87,628 shares of the company’s stock worth $4,250,000 after acquiring an additional 1,388 shares during the period. Municipal Employees Retirement System of Michigan increased its position in shares of Omnicell by 9.9% during the first quarter. Municipal Employees Retirement System of Michigan now owns 15,490 shares of the company’s stock worth $672,000 after acquiring an additional 1,390 shares during the period. Finally, Brinker Capital Inc. increased its position in shares of Omnicell by 18.8% during the first quarter. Brinker Capital Inc. now owns 9,225 shares of the company’s stock worth $400,000 after acquiring an additional 1,457 shares during the period. 98.79% of the stock is currently owned by institutional investors.

OMCL stock opened at $52.45 on Wednesday. The company has a market cap of $2.04 billion, a PE ratio of 99.25, a PEG ratio of 2.42 and a beta of 0.78. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.22 and a current ratio of 1.68. Omnicell has a one year low of $39.75 and a one year high of $55.40.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply